nabumetone
Sign in to saveclass=skin-invert-image|thumb|Three step CYP1A2 Mediated Metabolism of the prodrug Nabumetone to its active metabolite 6-MNA.
Key facts
- Drug.Verifiedfields
- changed
- Drug.verifiedrevid
- 462258056
- Drug.image
- Nabumetone.svg
- Drug.image_class
- skin-invert-image
- Drug.tradename
- Relafen
- Drug.MedlinePlus
- a692022
- Drug.DailyMedID
- Nabumetone
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- M01
- Drug.ATC_suffix
- AX01
- Drug.legal_AU
- S4
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
- Drug.protein_bound
- > 99% (active metabolite)
- Drug.metabolism
- Liver, to active metabolite 6-methoxy-2-naphthylacetic acid; 6-MNA
- Drug.elimination_half life
- 23 hours (active metabolite)
- Drug.excretion
- Kidney
- Drug.CAS_number
- 42924-53-8
via Wikipedia infobox
Article
5 sectionsContents
- Medical uses
- Side effects
- Society and culture
- Brand names
- References
class=skin-invert-image|thumb|Three step CYP1A2 Mediated Metabolism of the prodrug Nabumetone to its active metabolite 6-MNA.
Nabumetone, sold under the brand name Relafen among others, is a nonsteroidal anti-inflammatory drug (NSAID). Nabumetone was developed by Beecham and first received regulatory approval in 1991.